Variant-specific burden of SARS-CoV-2 in Michigan: March 2020 through November 2021

Joshua G. Petrie¹, Marisa C. Eisenberg², Adam S. Lauring³, Julie Gilbert², Samantha M. Harrison², Peter M. DeJonge⁴, Emily T. Martin²
¹Center for Clinical Epidemiology & Population Health, Marshfield Clinic Research Institute, Marshfield, WI
²Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI
³Departments of Internal Medicine and Microbiology and Immunology, University of Michigan, Ann Arbor, MI
⁴Wisconsin Department of Health Services

Abstract

Objectives: Accurate estimates of total burden of SARS-CoV-2 are needed to inform policy, planning and response. We sought to quantify SARS-CoV-2 cases, hospitalizations, and deaths by age in Michigan.

Methods: COVID-19 cases reported to the Michigan Disease Surveillance System were multiplied by age and time-specific adjustment factors to correct for under-detection. Adjustment factors were estimated in a model fit to incidence data and seroprevalence estimates. Age-specific incidence of SARS-CoV-2 hospitalization, death, and vaccination, and variant proportions were estimated from publicly available data.

Results: We estimated substantial under-detection of infection that varied by age and time. Accounting for under-detection, we estimate cumulative incidence of infection in Michigan reached 75% by mid-November 2021, and over 87% of Michigan residents were estimated to have had ≥1 vaccination dose and/or previous infection. Comparing pandemic waves, the relative burden among children increased over time. In general, the proportion of cases who were hospitalized or who died decreased over time.

Conclusions: Our results highlight the ongoing risk of periods of high SARS-CoV-2 incidence despite widespread prior infection and vaccination. This underscores the need for long-term
planning for surveillance, vaccination, and other mitigation measures amidst continued response to
the acute pandemic.

**Keywords**

COVID-19; SARS-CoV-2; Incidence; Seroprevalence; Infection; Case fatality

COVID-19 pandemic response has been challenged by rapidly changing circumstances
including the emergence of SARS-CoV-2 variants and a developing understanding of
the breadth and duration of vaccine-induced immunity. As policy-makers seek to update
decisions in an environment of shifting vaccination and infection patterns, a better
understanding of overall level of population immunity based on best-available surveillance
data is needed. However, accurately estimating the total burden of SARS-CoV-2 infection is
difficult.

Public health surveillance systems are challenged by persistent under-detection of cases,
particularly for those infections that do not require medical attention. Further, approximately
one third of all infections may be completely asymptomatic\(^1\)\(^2\). Under-detection is also
expected to vary by age and over time related to testing availability and testing behaviors\(^3\).
Seroprevalence studies can be helpful for surveillance and estimating the total burden
of infection\(^4\)\(^5\). However, seroprevalence estimates provide a snapshot of past and recent
infection that can be difficult to disentangle and can underestimate cumulative incidence of
infection due to waning antibody\(^6\).

The state of Michigan experienced four waves of SARS-CoV-2 transmission during the
COVID-19 pandemic through December 2021. Each pandemic wave has affected the
general population and healthcare systems in different ways suggesting changing patterns of
infection and severity by age. Michigan is also one of few states that experienced substantial
transmission of both the SARS-CoV-2 Alpha (B.1.1.7 lineage) and Delta (B.1.617.2 lineage)
variants\(^7\). We sought to quantify the burden of SARS-CoV-2 cases, hospitalizations, and
deaths by age and geography over time in Michigan by integrating public health surveillance
data, serial seroprevalence estimates, and genomic surveillance data. Burden estimates were
used to examine how the risk of hospitalization and death varied over time by age and
SARS-CoV-2 variant.

**METHODS**

**Cases**

Confirmed COVID-19 cases were those reported to the Michigan Disease Surveillance
System (MDSS) with those reported in the Michigan Department of Corrections system
excluded. MDSS data were accessed via data use agreement between the University of
Michigan and the Michigan Department of Health and Human Services. The IRB at the
University of Michigan Medical School reviewed this project and determined it to be exempt
secondary research for which informed consent is not required.

We used a model, adapted from Shioda et al., to estimate cumulative incidence of
infection from MDSS case incidence data and Michigan seroprevalence data from the
CDC’s Nationwide Commercial Lab Seroprevalence study while accounting for waning (Supplemental Methods; Supplemental Figure 1)\(^6,8\). We estimated case adjustment factors during 5 time periods (March to May 2020, June to September 2020, October 2020 to February 2021, March to May 2021, and June to November 2021) in age group-specific models (0–17, 18–49, 50–64, and ≥65 years). Parameters were estimated using Markov Chain Monte Carlo sampling; point estimates were taken as the median posterior sample, and 95% credible intervals (CrI) were taken as the 2.5th and 97.5th percentiles. As in Shioda et al., time from illness onset to seroconversion was assumed to follow a Weibull distribution with mean 11.5 days and SD 5.7 days\(^9\). We estimated the average time from seroconversion to seroreversion to have a mean 229.7 days (7.6 months) and SD 105.3 days by fitting a Weibull distribution, using a weighted least squares method, to published data on the duration of seropositivity measured by the Abbott ARCHITECT SARS-CoV-2 anti-nucleocapsid IgG immunoassay (Supplemental Figure 2)\(^10,11\). This assay was used in the Nationwide Commercial Lab Seroprevalence study in Michigan\(^4\).

Daily MDSS cases were multiplied by the age- and time-specific case adjustment factors and their 95% CrI to estimate a range of total infections. Adjusted total infections were aggregated by age group and week to state and public health preparedness region (Figure 1). Age groups used throughout this analysis are: 0–17, 18–19, 20–29, 30–39, 40–49, 50–59, 60–69, 70–79, and ≥80 years based on age granularity across data sources.

### Hospitalizations

Weekly, facility-level adult and pediatric inpatient admissions for confirmed or suspected COVID-19 were identified from HHS Protect\(^12\). Facilities were mapped to public health preparedness region, and weekly admission counts aggregated to state and region levels. Hospitalized cases were also identified from MDSS; because admission status is ascertained at the time of case investigation and individuals may not have been hospitalized yet, these data represent an underestimate of total hospitalizations, but age and geographic data are available. The total number of weekly admissions from HHS Protect were multiplied by week- and region-specific age distributions of hospitalized MDSS cases to estimate total hospitalizations in each age group, region, and week.

### Deaths

Weekly estimates of deaths were made using National Center for Health Statistics (NCHS) excess death estimates\(^13\) and confirmed and probable COVID-19 deaths reported to MDSS with those reported in the Michigan Department of Corrections system excluded. Weekly Michigan deaths were estimated as the total COVID-19 deaths reported to MDSS or the upper NCHS estimate of excess deaths, whichever was higher. The total combined MDSS/ NCHS weekly deaths were multiplied by the week- and region-specific age distributions of deaths from MDSS to estimate the total deaths in each age group, region, and week.

### Variant Prevalence

Proportions of Alpha and Delta variant and ancestral lineage SARS-CoV-2 viruses among all characterized viruses in Michigan were obtained from covariants.org for 2-week periods\(^14\). Counts of cases, hospitalizations, and deaths were multiplied by the week-specific variant
proportions to estimate cases, hospitalizations, and deaths attributable to Alpha, Delta, and ancestral viruses.

**Vaccination**

The proportion of the population receiving ≥1 dose of vaccine by age and region was calculated by week from publicly available data reported to the Michigan Care Improvement Registry\textsuperscript{15}. Vaccination data were available by the following age groups: 5–11, 12–15, 16–19, 20–29, 30–39, 40–49, 50–64, 65–74, ≥75 years. Vaccination counts were reassigned to the analysis age groups described under Cases as follows. If a vaccination age group spanned two analysis age groups, vaccination counts were assigned to each of the analysis age groups according to the proportion of age years contained in each age group. For example, 2/3 of the vaccinations in the 50–64 year vaccine age group were attributed to the 50–59 year analysis age group and 1/3 to the 60–69 year analysis age group. Vaccination counts from the ≥75 years vaccination age group were assigned to the 70–79 and ≥80 years analysis age groups according to the actual proportion of ≥75 year olds in Michigan who are also ≥80 years old (57%).

**Analysis**

The 16 highest incidence weeks of the Fall 2020, Spring 2021, and Fall 2021 waves of COVID-19 in Michigan were compared. The Fall 2020 wave was defined from 10/11/2020 through 1/30/2021, the Spring 2021 wave was defined from 2/28/2021 through 6/19/2021, and the Fall 2021 wave was defined from 7/25/2021 through 11/13/2021. Delta transmission in Fall 2021 had not peaked at the time of analysis. Age-specific estimated cases, hospitalizations, and deaths were plotted and compared across the waves, and by predicted variant status. Age- and region-specific proportions of cases who were hospitalized or died were also compared across waves. The effective reproduction number (R\textsubscript{e}) was estimated for Alpha, Delta, and ancestral lineage viruses over rolling 2-week intervals using the R EpiEstim package with a serial interval of mean 5.68 and SD 4.77 days\textsuperscript{16,17}. All analyses were completed using R (R Foundation for Statistical Computing; version 4.1.1).

**RESULTS**

During the Fall 2020 wave, 359,061 confirmed COVID-19 cases were reported in Michigan; 285,528 confirmed cases were reported in Spring 2021; and 262,258 confirmed cases were reported in Fall 2021 (Figure 2A). After applying age and time specific adjustment factors (Supplemental Table 1), we estimated that there were 1,649,547 total cases in the Fall 2020 wave, 1,594,954 total cases in the Spring 2021, and 3,329,748 total cases in Fall 2021. Alpha variant viruses were first detected in December 2020 (Figure 2B). The proportion of sequenced viruses identified as Alpha rapidly increased to nearly 50% by late February, and further increased to approximately 75% by early April. Delta variant viruses emerged in Michigan in April 2021 and accounted for nearly 100% of cases by mid-July 2021. Applying the estimated variant proportions to the estimated total weekly case time series, we estimated that there were 1,178,658 (74%) Alpha variant cases and 397,379 (25%) ancestral lineage cases in the Spring 2021 wave (Figure 2C). Ancestral lineage and Delta variant cases accounted for over 99% of infections in the Fall 2020 and Fall 2021 waves, respectively.
reproduction number for Alpha variant viruses was 12% (95% CrI: 12%, 13%) higher than that of ancestral viruses, and the reproduction number for Delta variant viruses was 91% (95% CrI: 91%, 92%) higher than that of Alpha variant viruses averaged over periods with overlapping circulation (Figure 2D).

Compared with the Fall 2020 wave in Michigan, there was a higher burden of infection among the youngest age group, but lower burden among the over 60 year age groups in Spring 2021 (Figure 3). The relationship between burden and age appeared similar comparing Alpha and non-Alpha variant infections during Spring 2021; Alpha variant infections consistently accounted for approximately 2/3 of the total infections in each age group. The Fall 2021 Delta variant wave had substantially higher numbers of infections than the 2 prior waves. Incidence was high in all age groups, but young children and middle-aged adults were most heavily affected. In all waves, hospitalization and death was unlikely in the youngest age groups; individuals over 60 were most likely to be hospitalized and to die in all waves.

In all waves, the proportion of cases who were hospitalized and the proportion of cases who died in Michigan increased substantially with age. Those in the middle age groups (20–29 through 40–49 years) were more likely to be hospitalized if infected in Spring 2021 than if infected in Fall 2020 (Figure 4A). However, this did not appear to be Alpha variant specific; the likelihood of hospitalization did not vary by lineage in any age group in the spring (Figure 4B). Cases who were ≥80 years were more likely to be hospitalized (20% [95% CrI: 18%, 23%] vs 8% [95% CrI: 7%, 11%] vs 4% [95% CrI: 3%, 7%]) and to die (10% [95% CrI: 9%, 11%] vs 3% [95% CrI: 3%, 4%] vs 2% [95% CrI: 2%, 4%]) if infected in Fall 2020 than if infected in Spring 2021 or Fall 2021 (Figures 4A and 4C). This also did not appear to be driven by Alpha variant circulation in Spring 2021 as the proportion of cases who died was similar comparing Alpha and ancestral infections (Figure 3D). Across all age groups, those with Delta variant infection in Fall 2021 were less likely to be hospitalized or die than those with ancestral or Alpha variant infections in previous waves.

Cumulative incidence by age group was tightly clustered between 3% and 8% just prior to the Fall 2020 wave, with the 0–17 year age group most likely (8%) and the 70–79 year age group least likely to have been previously infected (3%) (Figure 5A). Following the Fall 2020 wave, there was a wider range of age-specific cumulative incidence (13% to 28%) that generally decreased with increasing age. The 18–19 year age group was now most likely (28%), the 70–79 year age group remained least likely to have been infected (13%), and approximately 22% of the total population had been infected prior to the Spring 2021 wave. Following the Spring 2021 wave, overall cumulative incidence was 40% and ranged from 22% to 52% by age group. By November 12, 2021, overall cumulative incidence was 75% and ranged from 99% to 42% by age group. Cumulative incidence of infection did not vary as much by Michigan Public Health Preparedness Region as it did with age. However, the more rural Regions 7 and 8 consistently had the lowest cumulative incidence throughout the pandemic (Figure 5B).

Substantial vaccine uptake occurred among the 60–69, 70–79, and 80+ year age groups in early 2021, with an estimated 47%, 55%, and 28% having ≥1 dose of vaccine, respectively,
prior to the Spring 2021 wave (Figure 5C). Vaccination coverage increased in all age groups throughout Spring 2021 before slowing in the summer months, with final coverage ranging from >99% among 70–79 year olds to 19% among 0–17 year olds. Vaccination coverage did not vary substantially by Public Health Preparedness Region, but uptake was initially faster in Regions 7 and 8 possibly reflecting an older population on average (Figure 4D). Proportions receiving ≥1 vaccine dose or previous infection by the end of Spring 2021 ranged from 96% among 70–79 year olds to 55% among 0–17 year olds and followed the same patterns as vaccination coverage (Figures 4E and 4F). By November 13, 2021, our model estimates that over 87% of Michigan residents in all groups had at ≥1 vaccine dose and/or previous infection.

**DISCUSSION**

We estimated substantial under-detection of SARS-CoV-2 infection in Michigan that varied by age and time. Under-detection among children was highest prior to May 2020 with an estimated 83 infections for every reported case. Detection improved to 6 infections per report in the summer of 2020 before gradually worsening to 25 infections per report after June 2021. In contrast, infections among adults were much more likely to be detected throughout the pandemic, but under-detection increased over time with the highest numbers of infections per report (8 to 14) after June 2021. Accounting for under-detection, we estimate cumulative incidence of infection in Michigan reached 75\% by mid-November 2021. Further accounting for vaccination, we estimate the vast majority of Michiganders across all age groups had antigenic exposure to SARS-CoV-2 by mid-November 2021. These estimates can inform response and planning, for example, anticipating the scale of support services needed for individuals with post-acute COVID-19 symptoms.

Following initial Alpha variant introductions, Michigan experienced a surge of infections in Spring 2021 when many US states had declining incidence\(^7\). We estimate that Alpha variant infections accounted for approximately two thirds of all infections during Michigan’s Spring 2021 wave. Consistent with the observed rapid replacement, we estimated the Alpha \(R_e\) was 12\% higher than that of ancestral viruses. Alpha viruses were rapidly replaced by Delta in summer 2021, and we estimated that the Delta \(R_e\) was almost twice that of Alpha in periods of co-circulation. These estimates are somewhat lower than previous reports that found Alpha to be 40\% - 100\% more transmissible than ancestral SARS-CoV-2 viruses\(^{18,19}\), but similar to reports of increased transmissibility of Delta relative to Alpha\(^{20,21}\).

In the time since this analysis was carried out, Delta infections continued to rise in Michigan before being rapidly overtaken by Omicron resulting in record high daily infections. Michigan’s experience in the winter of 2022 makes it clear that combined levels of prior infection and vaccination that exceed 80\% are not sufficient to reach herd immunity. Suboptimal vaccine coverage, waning of natural and vaccine-induced immunity, and the emergence of more transmissible variants has facilitated ongoing transmission\(^{22-24}\). Indeed, it is unlikely that true herd immunity will be reached entirely ending SARS-CoV-2 transmission just as descendants of the 1968 and 2009 influenza pandemics continue to circulate today. This underscores the need for long-term planning in policy, public health

\(\text{J Med Virol. Author manuscript; available in PMC 2023 November 01.}\)
capacity, and research priorities. These results also suggest non-pharmaceutical mitigation measures may be needed during times of high transmission going forward.

We observed that the proportion of cases who were hospitalized or died decreased with each subsequent wave. Because of the ecologic nature of this analysis, we are unable to attribute reduced severity to a specific cause. However, our results do not suggest differences in the severity of Alpha and ancestral viruses in Spring 2021. Although differential severity has not been conclusively demonstrated, some studies have estimated Alpha and Delta are more severe than ancestral SARS-CoV-2, at least among unvaccinated individuals. COVID-19 vaccines have been effective in preventing severe outcomes of infection. This suggests that at least through the emergence of Delta, age-specific reductions in severity were likely due to vaccination and improved treatment options over time. Despite apparent reductions in severity, the emergence of more transmissible variants has stressed healthcare systems through large patient volumes and infections among healthcare workers.

A notable exception to the general trend of decreasing severity, is that adults <50 years were at increased risk of hospitalization in Spring 2021 relative to Fall 2020. It is possible that patterns in vaccine uptake could confound differences in severity over time. Among those prioritized for early vaccination, younger adults with chronic conditions had similar low intention to vaccinate as “essential workers” generally. Racial disparities in both vaccine uptake and severe outcomes of SARS-CoV-2 have also been demonstrated. If healthier adults were more likely to be vaccinated earlier, the remaining susceptible population may have been more likely to be hospitalized given infection. Factors associated with vaccine uptake warrant further investigation and consideration in analyses of differential severity.

Our results should be interpreted in the context of multiple limitations. 1) We were unable to account for reinfection, and vaccination was assumed to be independent of prior infection. 2) We relied on Michigan-specific data from the Nationwide Commercial Lab Seroprevalence study to calculate case adjustment factors to correct for under-detection. That study has its own limitations, and the representativeness of its sample to the Michigan population as a whole is unclear. 3) Case adjustment factors were sensitive to antibody waning rate assumptions. We found that the average time from seroconversion to seroreversion could not be estimated simultaneously with the adjustment factors due to identifiability issues, so we specified the former parameter from existing literature. 4) The case adjustment factors provided our main source of uncertainty. There are other sources of uncertainty that we were unable to propagate or account for. 5) SARS-CoV-2 sequence data reported to GISAID may not reflect true community variant proportions, particularly shortly after emergence when sampling may be biased toward outbreaks.

CONCLUSIONS

Our results highlight the ongoing risk of SARS-CoV-2 infection despite widespread prior infection and vaccination in the population. This underscores the need for long term planning for surveillance, vaccination, and other mitigation measures amidst continued response to the acute pandemic. The multiple streams of data on case incidence, infection outcomes, vaccine uptake, and genomic characterization that have facilitated the ongoing
COVID-19 pandemic response should be leveraged to inform response and updates to SARS-CoV-2 vaccine composition and delivery schedule.

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

**ACKNOWLEDGEMENTS:**

We thank Melissa Rolfes, Carrie Reed, Brendan Flannery, Miranda Delahoy, and Alicia Budd for extremely helpful conversations regarding methodology and preliminary results.

**FINANCIAL SUPPORT:**

Research reported in this publication was supported by the Centers for Disease Control and Prevention (contract numbers 75D301-20-C-0763 to E.T.M. and 75D301-21-C-11058 to A.S.L.), and by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (grant number K01AI141579 to J.G.P). The content is solely the responsibility of the authors and does not necessarily represent the official views of the Centers for Disease Control and Prevention or National Institutes of Health.

**DATA AVAILABILITY STATEMENT:**

Aggregated data and code that support the findings of this study are openly available at [https://github.com/jgpetrie/MI_COVID_burden](https://github.com/jgpetrie/MI_COVID_burden).

**References**

1. Oran DP, Topol EJ. The Proportion of SARS-CoV-2 Infections That Are Asymptomatic. Ann Intern Med. 2021;174(5):655–662. doi:10.7326/M20-6976 [PubMed: 33481642]
2. Sah P, Fitzpatrick MC, Zimmer CF, et al. Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis. PNAS. 2021;118(34). doi:10.1073/pnas.2109299118
3. Reese H, Iuliano AD, Patel NN, et al. Estimated Incidence of Coronavirus Disease 2019 (COVID-19) Illness and Hospitalization-United States, February-September 2020. Clin Infect Dis. 2021;72(12):e1010–e1017. doi:10.1093/cid/ciaa1780 [PubMed: 33237993]
4. Bajema KL, Wiegand RE, Cuffe K, et al. Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020. JAMA Internal Medicine. 2021;181(4):450–460. doi:10.1001/jama.2020.7976 [PubMed: 33231628]
5. Havers FP, Reed C, Lim T, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Intern Med. Published online July 21, 2020. doi:10.1001/jama.2020.4130
6. Shioda K, Lau MSY, Kraay ANM, et al. Estimating the Cumulative Incidence of SARS-CoV-2 Infection and the Infection Fatality Ratio in Light of Waning Antibodies. Epidemiology. 2021;32(4):518–524. doi:10.1097/ede.0000000000001361 [PubMed: 33935138]
7. Centers for Disease Control and Prevention. COVID Data Tracker. Centers for Disease Control and Prevention. Published March 28, 2020. Accessed February 14, 2022. [https://covid.cdc.gov/covid-data-tracker/#trends_dailycases](https://covid.cdc.gov/covid-data-tracker/#trends_dailycases)
8. Centers for Disease Control and Prevention. Nationwide COVID-19 Infection-Induced Antibody Seroprevalence (Commercial laboratories). Centers for Disease Control and Prevention. Published March 28, 2020. Accessed February 14, 2022. [https://covid.cdc.gov/covid-data-tracker/#national-lab](https://covid.cdc.gov/covid-data-tracker/#national-lab)
9. Iyer AS, Jones FK, Nodoushani A, et al. Dynamics and significance of the antibody response to SARS-CoV-2 infection. medRxiv. Published online July 20, 2020;2020.07.18.20155374. doi:10.1101/2020.07.18.20155374
10. Maine GN, Lao KM, Krishnan SM, et al. Longitudinal characterization of the IgM and IgG humoral response in symptomatic COVID-19 patients using the Abbott Architect. J Clin Virol. 2020;133:104663. doi:10.1016/j.jcv.2020.104663 [PubMed: 33161369]

11. Kahre E, Galow L, Unrath M, et al. Kinetics and seroprevalence of SARS-CoV-2 antibodies: a comparison of 3 different assays. Sci Rep. 2021;11(1):14893. doi:10.1038/s41598-021-94453-5 [PubMed: 34290329]

12. US Department of Health & Human Services. COVID-19 Reported Patient Impact and Hospital Capacity by Facility. Accessed February 14, 2022. https://healthdata.gov/Hospital/COVID-19-Reported-Patient-Impact-and-Hospital-Capa/anag-cw7u

13. National Center for Health Statistics. Excess Deaths Associated with COVID-19. Published February 9, 2022. Accessed February 14, 2022. https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm

14. Hodcroft EB. CoVariants: SARS-CoV-2 Mutations and Variants of Interest. Published 2021. Accessed February 14, 2022. https://covariants.org/

15. Michigan Department of Health and Human Services. COVID-19 Vaccine Coverage by County. Published 2021. Accessed February 14, 2022. https://www.michigan.gov/documents/coronavirus/Covid_Vaccine_Coverage_by_County_718469_7.xlsx

16. Cori A, Ferguson NM, Fraser C, Cauchemez S. A New Framework and Software to Estimate Time-Varying Reproduction Numbers During Epidemics. American Journal of Epidemiology. 2013;178(9):1505–1512. doi:10.1093/aje/kwt133 [PubMed: 24043437]

17. Reed IG, Walker ES, Landguth EL. SARS-CoV-2 Serial Interval Variation, Montana, USA, March 1–July 31, 2020 - Volume 27, Number 5—May 2021 - Emerging Infectious Diseases journal - CDC. doi:10.3201/eid2705.204663

18. Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372(6538):eabg3055. doi:10.1126/science.abg3055 [PubMed: 33658326]

19. Volz E, Mishra S, Chand M, et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021;593(7858):266–269. doi:10.1038/s41586-021-03470-x [PubMed: 33767447]

20. Allen H, Vusirikala A, Flannagan J, et al. Household transmission of COVID-19 cases associated with SARS-CoV-2 delta variant (B.1.617.2); national case-control study. The Lancet Regional Health – Europe. 2022;12. doi:10.1016/j.lanepe.2021.100252

21. Scientific Pandemic Influenza Group on Modelling, Operational sub-group (SPI-M-O). SPI-M-O: Consensus Statement on COVID-19. Published June 2, 2021. Accessed February 14, 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/993321/S1267_SPI-M-O_Consensus_Statement.pdf

22. Sah P, Moghadas SM, Vilches TN, et al. Implications of suboptimal COVID-19 vaccination coverage in Florida and Texas. The Lancet Infectious Diseases. 2021;21(11):1493–1494. doi:10.1016/S1473-3099(21)00620-4 [PubMed: 34627498]

23. Levin EG, Lustig Y, Cohen C, et al. Household transmission of COVID-19 vaccine over 6 Months. New England Journal of Medicine. 2021;385(24):e84. doi:10.1056/NEJMoa2114583 [PubMed: 34614326]

24. Wheatley AK, Juno JA, Wang JJ, et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat Commun. 2021;12(1):1162. doi:10.1038/s41467-021-21444-5 [PubMed: 33608522]

25. Twohig KA, Nyberg T, Zaidi A, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. The Lancet Infectious Diseases. 2022;22(1):35–42. doi:10.1016/S1473-3099(21)00475-8 [PubMed: 34461056]

26. Grint DJ, Wing K, Houlihan C, et al. Severity of SARS-CoV-2 variant B.1.1.7 in England. Clin Infect Dis. Published online September 6, 2021:ciab754. doi:10.1093/cid/ciab754

27. Thompson MG, Stenchjem E, Grams S, et al. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. N Engl J Med. 2021;385(15):1355–1371. doi:10.1056/NEJMoa2110362 [PubMed: 34496194]
28. Lewis NM, Naioti EA, Self WH, et al. Effectiveness of mRNA vaccines in preventing COVID-19 hospitalization by age and burden of chronic medical conditions among immunocompetent US adults, March-August 2021. J Infect Dis. Published online December 21, 2021:jiab619. doi:10.1093/infdis/jiab619

29. Nasreen S, Chung H, He S, et al. Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. Nat Microbiol. Published online February 7, 2022. doi:10.1038/s41564-021-01053-0

30. Nguyen KH. COVID-19 Vaccination Intent, Perceptions, and Reasons for Not Vaccinating Among Groups Prioritized for Early Vaccination — United States, September and December 2020. MMWR Morb Mortal Wkly Rep. 2021;70. doi:10.15585/mmwr.mm7006e3

31. Mackey K, Ayers CK, Kondo KK, et al. Racial and Ethnic Disparities in COVID-19-Related Infections, Hospitalizations, and Deaths : A Systematic Review. Ann Intern Med. 2021;174(3):362–373. doi:10.7326/M20-6306 [PubMed: 33253040]

32. Baack BN. COVID-19 Vaccination Coverage and Intent Among Adults Aged 18–39 Years — United States, March–May 2021. MMWR Morb Mortal Wkly Rep. 2021;70. doi:10.15585/mmwr.mm7025e2
Figure 1.
Map of Michigan Public Health Preparedness Regions.
Figure 2.
Epidemiology of the SARS-CoV-2 pandemic in Michigan. (A) Weekly reported confirmed and probable SARS-CoV-2 cases in Michigan. (B) Fraction of Alpha and Delta variant among characterized virus isolates. (C) Epidemic curve of estimated total, Alpha, Delta, and non-variant SARS-CoV-2 cases in Michigan; shaded gray areas highlight periods of analysis comparing Fall 2020 (Oct 11 - Jan 30), Spring 2021 (Feb 28 - Jun 19), and Fall 2021 (Jul 25 - Nov 13) waves. (D) Estimated reproduction number ($R_e$) comparing Alpha, Delta, and non-variant viruses.
Figure 3.
Estimated SARS-CoV-2 burden per 100,000 population by age in Michigan comparing estimated non-variant infections in Fall 2020 (Oct 11 - Jan 30), Alpha variant and non-variant infections in Spring 2021 (Feb 28 - Jun 19), and Delta variant infections in Fall 2021 (Jul 25 - Nov 13). The total height of the bars is the total number of cases in each age group i.e. hospitalizations and deaths were subtracted from the case counts. However, we do not know the proportion of hospitalized cases that died or the proportion of deaths that were not hospitalized so the combined height of those segments overestimates the total number of severe outcomes.
Figure 4.
Percent of SARS-CoV-2 cases in Michigan who were hospitalized (A) comparing Fall 2020 (Oct 11 - Jan 30), Spring 2021 (Feb 28 - Jun 19), and Fall 2021 (Jul 25 - Nov 13) waves, and (B) comparing estimated Alpha variant and non-variant infections in Spring 2021, and Delta variant infections in Fall 2021. Percent of SARS-CoV-2 cases in Michigan who died (C) comparing Fall 2020, Spring 2021, and Fall 2021 waves, and (D) comparing estimated Alpha variant and non-variant infections in Spring 2021, and Delta variant infections in Fall 2021.
Figure 5.
Cumulative percentage of Michigan population with SARS-CoV-2 infection, vaccination, or both by age group (A,C,E) and geographic region (B,D,F). Dotted vertical lines represent the start of the Fall 2020 (Oct 11 - Jan 30), Spring 2021 (Feb 28 - Jun 19), and Fall 2021 (Jul 25 - Nov 13) waves.